Levosimendan Fmk

Levosimendan, the active ingredient in Levosimendan Fmk, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac contractility and reduce symptoms of congestion.

GNH USA supplies Levosimendan Fmk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan acts as a calcium sensitizer and vasodilator in the treatment of acute heart failure.

Acute decompensated heart failure: improves cardiac output and alleviates signs of fluid overload.

Levosimendan may be associated with a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may be accompanied by vomiting. - Dizziness: often related to blood pressure changes. - Hypotension: transient reduction in systolic pressure. - Flushing: warm sensation with skin reddening. - Diarrhea: loose stools in some patients.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Sudden cardiac death: rare but reported in high‑risk populations.

Levosimendan requires careful monitoring and specific precautions. - Blood pressure monitoring: watch for significant hypotension during infusion. - Electrolyte assessment: correct imbalances before and during therapy. - Severe hypotension avoidance: contraindicated in patients with uncontrolled low blood pressure. - Renal impairment caution: dose adjustment may be needed in severe renal dysfunction. - Hepatic impairment caution: monitor liver function tests. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes.

Major Interactions (Avoid): - Nitrates or other potent vasodilators: risk of profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: additive effect on blood pressure and electrolyte balance. - ACE inhibitors or ARBs: may enhance hypotensive response. - Beta‑blockers: monitor cardiac output and heart rate. - Other inotropes: potential for excessive cardiac stimulation. - Calcium channel blockers: may affect vascular tone.